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Introduction
DNA methylation of cytosine residues in the context of the sequence 5'-cytosineguanosine (CpG) in gene promoter regions is an epigenetic mechanism that controls gene transcription, genome stability and genetic imprinting (Robertson, 2005) . This process is regulated by DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b) in the presence of s-adenosyl-methionine (SAM) that serves as a methyl donor for methylation of cytosine residues at the C-5 position to yield 5-methylcytosine (Robertson, 2005) .
Aberrant hypermethylation of promoter CpG rich regions (>55% CG content, the socalled CpG islands) of tumor suppressor genes (TSGs) result in transcriptional silencing in a variety of solid tumors and blood cancers (Yoo and Jones, 2006) . In-vitro and in-vivo treatment with DNA methylation inhibitors has proven to be effective in restoring gene expression and normal patterns of differentiation and apoptosis in malignant cells (Yoo and Jones, 2006) . Two nucleoside analogs (azanucleosides) with hypomethylating activity, i.e., 5-aza-2'-deoxycytidine (decitabine) and 5-azacytidine, have recently been approved by the Food and Drug Administration for the treatment of myelodysplastic syndrome, clonal myeloid disorders and acute myeloid leukemia (AML) (Silverman et al., 2002; Kantarjian et al., 2006) . Clinical trials with these agents are ongoing in other type of cancers with encouraging results (Lyko and Brown, 2005) . However, toxicities (i.e, myelosuppression) inherent to the cell cycle phase specificity of nucleoside analogs pose significant limitations to the use of these drugs, especially in patients with solid tumors. Thus, JPET #147934 6 discovery and development of novel, effective DNA methylation inhibitors that have a more favorable toxicity profile are essential to broaden the spectrum of epigenetic targeting therapeutic strategies (Cheng et al., 2003; Fang et al., 2003; Segura-Pacheco et al., 2003; Villar-Garea et al., 2003; Lee et al., 2005; Mund et al., 2006; Winquist et al., 2006) . To date, however, among these evaluated hypomethylating non-nucleoside agents, e.g. procaine, procainamide, RG108, none shows pharmacologic activity comparable to that of azanucleosides (Chuang et al., 2005) . Nevertheless, the recent discovery of the hypomethylation activity of EGCG (Fang et al., 2003) , a major polyphenol in green tea and other dietary polyphenols, has paved the way aiming to identify novel and efficient DNA methylation inhibitors from plant-derived natural products (phytochemicals).
Parthenolide (PN), the principal bioactive sesquiterpene lactone component of feverfew, has been used for the treatment of fever, migraine and arthritis (Kwok et al., 2001 ). Because of inhibition activity to nuclear transcription factor (NF-κB), this compound has been tested for anti-cancer activities with encouraging results both in invitro and in-vivo (Wiedhopf et al., 1973; Woynarowski and Konopa, 1981; Patel et al., 2000; Garcia-Pineres et al., 2001; Garcia-Pineres et al., 2004; Nakshatri et al., 2004; Won et al., 2004; Guzman et al., 2005; Steele et al., 2006) . Mechanistic studies demonstrated that parthenolide covalent blocks the thiol group of cysteine at the active site of p65 NF-κB through its highly electrophilic γ-methylene lactone ring. This effect may play a pivotal role in apoptosis (Garcia-Pineres et al., 2001; Garcia-Pineres et al., 2004) .
Therefore, we postulated here that a similar interaction could occur between parthenolide and DNMT1. In fact, in DNA methylation, it has been shown that prior to the process, This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 6, 2009 as DOI: 10.1124 at ASPET Journals on jpet.aspetjournals.org Downloaded from JPET #147934 7 cytosine is "flipped out" of DNA double helix to form a transition state with a catalytic functional thiol of C1226 in the catalytic site of DNMT1 resulting in a reactive 4, 5-enamine followed by β -elimination, which releases DNMT1 and the product 5-methylcytosine (Santi et al., 1983) . It is possible that parthenolide covalently binds to the C1226 thiol group and inhibits the activities of this enzyme without the need to be incorporated into DNA, as is the case for azanucleosides, although DNMT1 turnover is also increased in the presence of azanucleosides (Ghoshal et al., 2005) . Recently, bortezomib, a FDA approved proteasomal inhibitor that inhibits NF-κB translocation to nucleus, was found to be a novel DNA methylation inhibitor, possibly through modulation of DNA methyltransferase activity by disruption of Sp1/NF-κB complex in leukemia cells (Liu et al., 2008) . Therefore, we hypothesized that, in addition to chemical inhibition of DNMT1, parthenolide acts as a NF-κB inhibitor and also modulates the DNMT1 expression in leukemia cells.
In this study, we validate these hypotheses by demonstrating for the first time that parthenolide indeed inhibits DNMT activity and down-regulates DNMT1 resulting in significant DNA hypomethylation and gene re-expression both in-vitro and in vivo. Our study emphasizes the importance of testing parthenolide as an alternative treatment for abnormal epigenetic patients unresponsive to current DNA methylation inhibitor therapy and, perhaps, for other solid tumors and non-proliferating cancers characterized by aberrant DNA methyltransferase activities.
This article has not been copyedited and formatted. The final version may differ from this version. (Sali and Blundell, 1993) . Together with the cofactor SAM and flipped cytosine substrate plus 15Å truncated octahedron TIP3P water box, the resulting structure was energy minimized.
Docking of Parthenolide.
AutoDock version 4.0.0 (Huey et al., 2007) was used for the docking simulation. We selected the Lamarckian genetic algorithm (LGA) for ligand conformational searching, because it has enhanced performance relative to the simulated annealing or the simple genetic algorithm (Friesner et al., 2004) . For parthenolide, all hydrogen atoms were added and Gasteiger charges (Morris et al., 1996) were assigned; then non-polar hydrogen atoms were merged. 80×100×70 3-D affinity grids centered on the empty binding site with 0.375 Å spacing were calculated for each of the following atom types: a) protein: A (aromatic C), C, HD, N, NA, OA, SA; b) ligand:
C, A, OA, HD, e (electrostatic) and d (desolvation) using Autogrid4. The ligand's translation, rotation and internal torsions are defined as its state variables and each gene represents a state variable.
LGA adds local minimization to the genetic algorithm, enabling modification of the gene population. The docking parameters were as follows:
trials of 100 dockings, population size of 250, random starting position and conformation, translation step ranges of 2.0 Å, rotation step ranges of 50º, elitism of 1, mutation rate of 0.02, crossover rate of 0.8, local search rate of 0.06, and 50 million energy evaluations.
Final docked conformations were clustered using a tolerance of 1.5 Å root-mean-square . Extraction Reagent; Pierce, Rockford, IL) and nuclear extracts were prepared using NE-PER (Nuclear and Cytoplasmic Extraction Reagent; Pierce, Rockford, IL). EMSA with total extracts or nuclear extracts and 32 P-labeled DNMNT1 promoter oligos were performed as previously described (Liu et al., 2008) . For antibody-supershift assays, a 2 μ g aliquot of antibodies (Sp1, NF-κB/p65) or control rabbit IgG were added after the binding reactions had proceeded for 10 min, and further incubated for another 20 min before gel loading. Alternatively, nuclear extracts were pre-incubated with individual PCRs were carried out in a 100 μL volume containing 10 μL of buffer (10x), 2 μL of each primer (10 μM), 2 μL of (10 mM) dNTPs, 2 U of Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA), 70.6 μL ddH2O and 10 μL of bisulfite treated DNA. PCR amplifications were performed in a GeneAmp 9700 thermal cycler (Perkin-Elmer, Norwalk, CT). PCR products were purified using QIAquick columns and eluted in water.
In-vitro
This article has not been copyedited and formatted. The final version may differ from this version. min. Fully methylated PCR products were purified using the QIAquick PCR Purification kit (Qiagen, Minneapolis, MN), according to the manufacturer's instructions and 200 ng of the purified DNA was hydrolyzed and the concentrations of 5mdC and 2dC in the hydrolysate were measured by LC-MS/MS using the conditions as described above. The methylation level of some samples was also analyzed using bisulfite-sequencing as previously described (Rush et al., 2004) . Primers and PCR conditions were the same as those used for gene-specific LC-MS/MS. Ten-12 clones were randomly selected for sequencing from each transfection. (Hwang et al., 2006) and its inhibitory activity on M. SssI was evaluated using the same assay. As shown in Figure 3 , no dosedependent decrease in fluorescence intensity from 1 nM to 100 μM was found, indicating that there is no inhibitory activity of parthenolideA on M. SssI. This result suggests that the γ-methylene lactone is critical for the inhibitory activity of parthenolide and this may be due to the potential formation of a covalent Michael adduct of parthenolide with M.
SssI, resulting in blocking the functional thiolate (C142) of the enzyme.
The inhibitory activity of parthenolide on DNMT1 was also evaluated using DNMT1 activity assay Kit (Epigentek, CO). A similar EC50 of 3.5 μM was determined, indicating that our assay of M. SssI activity can reflect the actual inhibitory activities of DNMT1 inhibitors on DNMT1. lines remained unchanged when exposed to 3 μM parthenolide. However, when exposed to 10 μM parthenolide, DNMT1 protein level was totally depleted in MV4-11 cells and decreased by about 50% in Kasumi-1 cells as shown in (Figure 4) . These results demonstrated that perturbation on DNMT1 protein levels by parthenolide was dose-and cell-type dependent and its down-regulation requires relatively high concentration of parthenolide.
Dose-dependent Down-regulation of DNMT1 Proteins by

Down-regulation of DNMT1 of Parthenolide May be Associated with Its Cell
Cycle Arrest and Apoptosis-induction. Previous study demonstrated that DNMT1 levels varies in cell cycles (Robertson et al., 2000) and extremely low in the SubG1 phase and over-expressed in the S phase. To understand whether the down-regulation of DNMT1 protein level is cell-cycle dependent, cell cycle distribution of MV4-11 cells treated with 0, 3 and 10 μM parthenolide at 24 h, at which, DNMT1 protein level was not known to change nor depleted, was analyzed by flow cytometry. As shown in Figure 5A , more than half of untreated MV4-11 cells (69.9%) were in the G0/G1 phase and about 6.66, 15.09 and 9.1 % of cells were in the subG1, S and G2/M phase, respectively. As shown in Figure 5B , there was no significant change of the cell population distribution of (Figure 4) . Therefore, parthenolide-induced cell cycle arrest may at least partially account for the alteration of DNMT1 protein levels in MV4-11 cells. Consistent with the cell cycle arrest, a significant apoptotic effect (about 73%) was observed in 10-μM parthenolide-treated MV4-11 cells compared to 7.5% in the control.
Down-regulation of DNMT1 Expression May be Associated with Its
Disruption of the Physical Interaction of Sp1 and DNMT1 Promoter. In addition to the potential association of alteration of DNMT1 protein levels with the cell cycle arrest in MV4-11 cells induced by parthenolide, we have recently found that the Sp1-NF-κB/p65 complex is a novel modulator of DNMT1 expression by physical interaction with the promoter of DNMT1 (Liu et al., 2008) . Disruption of Sp1-NF-κB/p65 complex by a proteasomal inhibitor bortezomib in MV4-11 cells can down-regulate DNMT1 transcriptional level and protein level (Liu et al., 2008) . In addition, parthenolide has been found to inhibit the activation of NF-κB possibly through alkylation of Cys 38 of p65 in various cancer cells (Garcia-Pineres et al., 2001; Garcia-Pineres et al., 2004) .
Therefore, it is hypothesized that the down-regulation of DNMT1 might also be associated with disruption of complex of Sp1-NF-κB/p65. To understand this mechanism for down-regulation of DNMT1 in MV4-11 cells induced by parthenolide, the Sp1 expression of 10 μM-parthenolide treated MV4-11 cells was examined, and it was found analysis of these genomic DNA extracted from these MV4-11 cells using a recently established LC-MS/MS method showed that parthenolide at the dose induced a 25% decrease (p=0.029, n=3, two sample t-test) in global DNA methylation relative to the untreated baseline ( Figure 7A ) in 24 h and to the same degree of hypomethylation induced by decitabine; however, no significant changes in global DNA methylation for 48 and 72 h incubation was found (data not shown). Similarly, the global DNA methylation also decreased about 25% in K562 cells exposed to 5 μM parthenolide in 24 h and no significant change for 48 and 72 h incubation as shown in Figure 7A . This result suggested that parthenolide is an effective DNA methylation inhibitor.
Having found the significant in-vitro hypomethylation activity of parthenolide, we proceed to confirm this activity in-vivo and a MV4-11 engrafted nude mouse model (Lopes de Menezes et al., 2005) was used. Levels of global DNA methylation levels in these MV4-11 xenograft tumors were then compared with those of the untreated controls (i.e., vehicle only). Consistent with our in-vitro results, we found a significant decrease in DNA methylation level (30%, p=0.05) ( Figure 7B ) at 10 mg/kg of parthenolide.
Additionally, a pilot anti-tumor growth activity study with parthenolide in a MV4-11 engrafted nude mice at daily x 5 i.p. dose of 4 mg/kg was also carried out and the results demonstrated that the tumor size decreased 37% relative to the control (p=0.006) ( Figure   7C ). This dose was selected based on a reported preclinical pharmacology study with was down-regulated in parthenolide-treated MV4-11 engrafted tissues compared to that of the placebo-treated tissues as shown in Figure 7D . (Santi et al., 1983) , 2) non-covalent blocking of DNMT1 catalytic active site (i.e., EGCG and RG108) (Fang et al., 2003; Mund et al., 2006) , 3) interruption of binding site of DNMT1 to DNA (i.e., procaine and procainamide) (Villar-Garea et al., 2003; Lee et al., 2005) , 4) degradation of DNMT1 (i.e., decitabine (Ghoshal et al., 2005) , and 5) suppression of DNMT1 expression (i.e., anti-sense MG-98, miR29b) (Winquist et al., 2006; Fabbri et al., 2007) . Among these, DNMT1 covalent-trapping compounds represented by azanucleosides and down-regulation of DNMT1 by its antisense oligonucleotides (Winquist et al., 2006) and microRNAs (Fabbri et al., 2007) compared to azanucleosides and oligonucleotides (Chuang et al., 2005) .
Hypomethylation
This article has not been copyedited and formatted. The final version may differ from this version. Among these, sesquiterpene lactones (SLs) are biologically active and structurally diversified herbal components and one of the SLs, parthenolide, was previously used as an anti-inflammatory drug. Pharmacologically, parthenolide has been shown to inhibit NF-κB and possesses significant anti-cancer effects (Wiedhopf et al., 1973; Woynarowski and Konopa, 1981; Patel et al., 2000; Garcia-Pineres et al., 2001; Kwok et al., 2001; Garcia-Pineres et al., 2004; Nakshatri et al., 2004; Won et al., 2004; Guzman et al., 2005; Steele et al., 2006) . Previous studies on molecular mechanism in parthenolidetreated cells, there is a covalent blocking of the thiol group of cysteine in the active site of p65, which plays a pivotal role in the apoptotic process (Garcia-Pineres et al., 2001; Garcia-Pineres et al., 2004) .
Recently, a DNMT1 homology modeling (Siedlecki et al., 2003) has been built to provide mechanism-based virtual databases of candidate compounds that inhibit human DNA methyltransferases. As proof of principle, we adapted and improved the DNMT1 homology modeling and docked parthenolide. We found that parthenolide might be particularly effective in inhibiting DNMT activity through initial non-covalent binding to the catalytic pocket of DNMT1, possibly in competition with the substrate cytosine and co-factor SAM (Figure 2A) . Subsequently, the γ-methylaene lactone moiety may covalently bind with the thiol group of DNMT1, thus inhibiting the enzyme activity. We also docked EGCG (Fang et al., 2003) and RG-108 (Mund et al., 2006) , two published DNMT1 inhibitors, with results consistent with previously published (Fang et al., 2003; Mund et al., 2006) . 
